These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 28634669)

  • 1. Yttrium-90 (Y-90) Resin Microsphere Therapy for Patients with Unresectable Hepatocellular Carcinoma: a Single-Center Experience.
    İnce S; Karaman B; Alagoz E; Karadurmuş N; Şan H; Erçin CN; Arslan N
    J Gastrointest Cancer; 2017 Sep; 48(3):281. PubMed ID: 28634669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partition Model-Based 99mTc-MAA SPECT/CT Predictive Dosimetry Compared with 90Y TOF PET/CT Posttreatment Dosimetry in Radioembolization of Hepatocellular Carcinoma: A Quantitative Agreement Comparison.
    Gnesin S; Canetti L; Adib S; Cherbuin N; Silva Monteiro M; Bize P; Denys A; Prior JO; Baechler S; Boubaker A
    J Nucl Med; 2016 Nov; 57(11):1672-1678. PubMed ID: 27307346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
    Wang EA; Stein JP; Bellavia RJ; Broadwell SR
    Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yttrium-90 (Y-90) resin microsphere therapy for patients with unresectable hepatocellular carcinoma. Identification of successful treatment response predictors and patient selection.
    Arslan N; Ince S; Okuyucu K; San H; Alagoz E; Karadurmus N; Karaman B; Ercin CN
    Ann Ital Chir; 2021; 92():623-631. PubMed ID: 35166222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for hepatic neuroendocrine metastases: initial experience at a single center.
    Arslan N; Emi M; Alagöz E; Ustünsöz B; Oysul K; Arpaci F; Uğurel S; Beyzadeoğlu M; Ozgüven MA
    Vojnosanit Pregl; 2011 Apr; 68(4):341-8. PubMed ID: 21627019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
    Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for unresectable primary and metastatic liver tumors.
    Kucuk ON; Soydal C; Lacin S; Ozkan E; Bilgic S
    World J Surg Oncol; 2011 Aug; 9():86. PubMed ID: 21819613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.
    Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A
    Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of PERCIST and RECIST criteria for evaluation of therapy response after yttrium-90 microsphere therapy in patients with hepatocellular carcinoma and those with metastatic colorectal carcinoma.
    Sager S; Akgün E; Uslu-Beşli L; Asa S; Akovali B; Sahin O; Yeyin N; Demir M; Abuqbeitah M; Gülsen F; Sayman H; Sönmezoglu K
    Nucl Med Commun; 2019 May; 40(5):461-468. PubMed ID: 30896544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers.
    Kennedy AS; Nutting C; Coldwell D; Gaiser J; Drachenberg C
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1552-63. PubMed ID: 15590187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres.
    Lau WY; Ho S; Leung TW; Chan M; Ho R; Johnson PJ; Li AK
    Int J Radiat Oncol Biol Phys; 1998 Feb; 40(3):583-92. PubMed ID: 9486608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SPECT/CT with 99mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancer.
    Hamami ME; Poeppel TD; Müller S; Heusner T; Bockisch A; Hilgard P; Antoch G
    J Nucl Med; 2009 May; 50(5):688-92. PubMed ID: 19372479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of Technetium-99m Macroaggregated Albumin and Yttrium-90 Glass Microsphere Biodistribution in Hepatocellular Carcinoma: A Retrospective Review of Pretreatment Single Photon Emission CT and Posttreatment Positron Emission Tomography/CT.
    Haste P; Tann M; Persohn S; LaRoche T; Aaron V; Mauxion T; Chauhan N; Dreher MR; Johnson MS
    J Vasc Interv Radiol; 2017 May; 28(5):722-730.e1. PubMed ID: 28238581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET-CT post therapy dosimetry in radioembolization with resin
    Richetta E; Pasquino M; Poli M; Cutaia C; Valero C; Tabone M; Paradisi BP; Pacilio M; Pellerito RE; Stasi M
    Phys Med; 2019 Aug; 64():16-23. PubMed ID: 31515015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: the tumor selectivity of the treatment as a function of tumor to liver flow ratio.
    Gulec SA; Mesoloras G; Dezarn WA; McNeillie P; Kennedy AS
    J Transl Med; 2007 Mar; 5():15. PubMed ID: 17359531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive Value of 99mTc-MAA SPECT for 90Y-Labeled Resin Microsphere Distribution in Radioembolization of Primary and Secondary Hepatic Tumors.
    Ilhan H; Goritschan A; Paprottka P; Jakobs TF; Fendler WP; Todica A; Bartenstein P; Hacker M; Haug AR
    J Nucl Med; 2015 Nov; 56(11):1654-60. PubMed ID: 26315830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microsphere localization and dose quantification using positron emission tomography/CT following hepatic intraarterial radioembolization with yttrium-90 in patients with advanced hepatocellular carcinoma.
    Lea WB; Tapp KN; Tann M; Hutchins GD; Fletcher JW; Johnson MS
    J Vasc Interv Radiol; 2014 Oct; 25(10):1595-603. PubMed ID: 25156647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors.
    Leung TW; Lau WY; Ho SK; Ward SC; Chow JH; Chan MS; Metreweli C; Johnson PJ; Li AK
    Int J Radiat Oncol Biol Phys; 1995 Nov; 33(4):919-24. PubMed ID: 7591903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres.
    Flamen P; Vanderlinden B; Delatte P; Ghanem G; Ameye L; Van Den Eynde M; Hendlisz A
    Phys Med Biol; 2008 Nov; 53(22):6591-603. PubMed ID: 18978442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Yttrium-90 microsphere selective internal radiation therapy and external beam radiotherapy in patients with hepatocellular carcinoma: From clinical aspects to dosimetry.
    Wang TH; Huang PI; Hu YW; Lin KH; Liu CS; Lin YY; Liu CA; Tseng HS; Liu YM; Lee RC
    PLoS One; 2018; 13(1):e0190098. PubMed ID: 29293557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.